脑膜瘤的分子分型与分级
本综述通过PubMed检索脑膜瘤基因组与分子特征文献,指出当前主要基于组织学及有限分子特征的WHO分级不能一致反映生物学行为,导致治疗不足或过度;整合组织病理、突变分析、DNA拷贝数变化和DNA甲基化谱可更全面捕获临床与生物学异质性,未来分类方案可能受益于这种整合方法。
要点
- 当前WHO脑膜瘤分级主要基于组织学及有限分子特征,不能一致反映生物学行为。
- 整合组织病理、突变分析、DNA拷贝数变化和DNA甲基化谱可更全面捕获肿瘤异质性。
- 脑膜瘤诊断与分类最好结合组织病理与基因组及表观基因组因素。
核心结论
- 脑膜瘤诊断与分类最好结合组织病理与基因组及表观基因组因素,未来分类方案可能受益于这种整合方法。
研究设计与样本
- 综述,通过PubMed筛选脑膜瘤基因组格局与分子特征的现有文献。
主要发现
- 整合组织病理、突变分析、DNA拷贝数变化、DNA甲基化谱及可能其他模态可更全面捕获脑膜瘤临床与生物学异质性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Meningiomas are the most common primary intracranial tumor in older adults (Ostrom et al. in Neuro Oncol 21(Suppl 5):v1-v100, 2019). Treatment is largely driven by, in addition to patient characteristics and extent of resection/Simpson grade, the World Health Organization (WHO) grading of meningiomas. The current grading scheme, based predominantly on histologic features and only limited molecular characterization of these tumors (WHO Classification of Tumours Editorial Board, in: Central nervous system tumours, International Agency for Research on Cancer, Lyon, 2021), (Mirian et al. in J Neurol Neurosurg Psychiatry 91(4):379-387, 2020), does not consistently reflect the biologic behavior of meningiomas. This leads to both under-treatment and over-treatment of patients, and hence, suboptimal outcomes (Rogers et al. in Neuro Oncol 18(4):565-574). The goal of this review is to synthesize studies to date investigating molecular features of meningiomas as they relate to patient outcomes, in order to clarify best practices in assessing and, therefore, treating meningiomas. METHODS: The available literature of genomic landscape and molecular features of in meningioma was screened using PubMed. RESULTS: Greater understanding of meningiomas is reached by integrating histopathology, mutational analysis, DNA copy number changes, DNA methylation profiles, and potentially additional modalities to fully capture the clinical and biologic heterogeneity of these tumors. CONCLUSION: Diagnosis and classification of meningioma is best accomplished using a combination of histopathology with genomic and epigenomic factors. Future classification schemes may benefit from such an integrated approach.
引用
- Nasrallah MP, Aldape KD. Molecular classification and grading of meningioma. J Neurooncol. 2023. PMID: 36802047. doi:10.1007/s11060-022-04228-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。